首页> 外文期刊>Endocrine practice: official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists >Vitamin D receptor gene polymorphism and its association with 1,25-dihydroxyvitamin D 3 in patients with graves disease in an Egyptian population: A pilot study
【24h】

Vitamin D receptor gene polymorphism and its association with 1,25-dihydroxyvitamin D 3 in patients with graves disease in an Egyptian population: A pilot study

机译:埃及人群严重坟墓患者维生素D受体基因多态性及其与1,25-二羟基维生素D 3的关联

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: To study the association of vitamin D receptor (VDR) gene polymorphisms (BsmI, ApaI, and TaqI) with susceptibility to Graves disease (GD) in Egyptian patients and their correlation with serum levels of 1,25-dihydroxyvitamin D 3 [1,25(OH)2D3].Methods: The current study consisted of 90 patients with GD (65 women and 25 men), with ages ranging from 25 to 55 years. A control group of 55 healthy euthyroid subjects (40 women and 15 men) with matched ages were included in the study. Genotyping was performed by restriction fragment length polymorphism analysis. Serum levels of 1,25(OH)2D3 were measured with use of radioimmunoassay in the patients and the control subjects.Results: The distribution of genotype frequencies differed significantly between patients with GD and control subjects (BsmI: χ 2 = 10.627, P = .004; ApaI: χ 2 = 12.581, P = .001; TaqI: χ 2 = 9.591, P = .008). We found overexpression of the VDR BsmI "bb" (odds ratio, 2.360; 95% confidence interval [CI], 1.11 to 4.996), ApaI "aa" (odds ratio, 2.785; 95% CI, 1.116 to 6.933), and TaqI "TT" (odds ratio, 3.047; 95% CI, 1.478 to 6.283) genotypes in patients with GD in comparison with control subjects. In contrast, no correlation was observed with respect to the 1,25(OH)2D3 levels with BsmI, ApaI, and TaqI genotypes (P.05) on the analysis of variance test.Conclusion: These data suggested that BsmI, ApaI, and TaqI polymorphisms in the VDR gene were associated with susceptibility to GD, whereas BsmI, ApaI, and TaqI polymorphisms were not associated with serum levels of 1,25(OH)2D3.
机译:目的:研究埃及患者维生素D受体(VDR)基因多态性(BsmI,ApaI和TaqI)与Graves病(GD)的易感性及其与血清1,25-二羟基维生素D 3的相关性[1 ,25(OH)2D3]。方法:本研究包括90例GD患者(65名女性和25名男性),年龄在25至55岁之间。本研究纳入了55名年龄匹配的健康甲状腺正常受试者(40名女性和15名男性)作为对照组。通过限制性片段长度多态性分析进行基因分型。用放射免疫法测定了患者和对照组的血清1,25(OH)2D3水平。结果:GD患者与对照组的基因型频率分布差异显着(BsmI:χ2 = 10.627,P = .004; ApaI:χ2 = 12.581,P = 0.001; TaqI:χ2 = 9.591,P = 0.008)。我们发现VDR BsmI“ bb”(赔率,2.360; 95%置信区间[CI],1.11至4.996),ApaI“ aa”(赔率,2.785; 95%CI,1.116至6.933)和TaqI过表达与对照组相比,GD患者的“ TT”基因型(优势比为3.047; 95%CI为1.478至6.283)。相比之下,在方差分析中,与BsmI,ApaI和TaqI基因型(P> .05)的1,25(OH)2D3水平没有相关性。结论:这些数据表明BsmI,ApaI, VDR基因中的TaqI和TaqI多态性与对GD的易感性相关,而BsmI,ApaI和TaqI多态性与血清1,25(OH)2D3的水平不相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号